AJ Vaccines A/S

AJ Vaccines is a global pharmaceutical company, established in 2017 after the acquisition of Statens Serum Institut (SSI) vaccine production. Today, we have a state-of-the-art production with 100 years of experience in producing high quality vaccines and biologics. We develop and manufacture vaccines against serious infectious diseases such as tetanus, diphtheria, tuberculosis (TB), pertussis (whooping cough) and polio. AJ Vaccines is proudly committed to support the Global Polio Eradication Initiative (GPEI), with our dose sparing technology providing a significant contribution to expanding inactivated polio vaccine supply. In addition, we manufacture Tuberculin Skin Test for screening and diagnosing of high-risk patients for infection with TB, as well as BCG Culture (Danish Strain 1331) for the standard treatment of intermediate and high-risk non-muscle invasive bladder cancer (NMIBC).